PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1446969
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1446969
According to Stratistics MRC, the Global High Pressure Contrast Media Injector Market is accounted for $177.6 million in 2023 and is expected to reach $447.2 million by 2030 growing at a CAGR of 14.1% during the forecast period. A high-pressure contrast media injector is a medical device used in radiology and diagnostic imaging procedures, particularly computed tomography (CT) scans and angiography. The device typically consists of a syringe or reservoir containing the contrast media, a high-pressure injector system, and a computerized control panel. These injectors deliver contrast media at a controlled rate and pressure, ensuring consistent and uniform distribution throughout the vascular system. This results in improved visualization of blood vessels, organs, and tissues, leading to clearer and more detailed images.
According to the World Health Organization (WHO) estimates, cancer is the one of the leading causes of death in majority of countries globally.
Rising demand for minimally invasive surgeries
Minimally invasive surgical techniques have gained popularity due to their potential benefits compared to traditional open surgeries. As minimally invasive procedures become more widespread across various medical specialties, the need for high-quality imaging guidance during these procedures becomes paramount. Additionally, high-pressure contrast media injectors play a crucial role in providing real-time visualization of blood vessels, organs, and tissues during minimally invasive surgeries, such as endovascular procedures, interventional radiology, and laparoscopic surgeries.
Risk of adverse events
High-pressure contrast media injectors are medical devices that administer contrast agents directly into the patient's bloodstream. As such, there is a risk of adverse events associated with contrast administration, such as allergic reactions, extravasation, and anaphylaxis. Furthermore, contrast-induced nephropathy is a potential complication characterized by acute kidney injury following contrast media exposure, particularly in patients with pre-existing renal impairment. The occurrence of adverse events can result in patient harm, increased healthcare costs, and liability risks for healthcare providers and facilities. These factors limit the market's expansion.
Advancements in imaging technologies
As imaging technologies evolve and become more sophisticated, there is a growing need for contrast-enhanced imaging procedures to provide detailed and accurate diagnostic information. High-pressure contrast media injectors are essential components in contrast-enhanced imaging procedures, as they ensure the precise and controlled delivery of contrast agents into the patient's bloodstream. Moreover, by delivering contrast media at high pressures and controlled rates, these injectors optimize the distribution of contrast agents throughout the vascular system, enabling clearer visualization of anatomical structures and abnormalities. As a result, advancements in imaging technologies are a significant factor propelling market expansion.
Competition from alternative imaging modalities
Modalities such as ultrasound, magnetic resonance imaging (MRI), and optical coherence tomography (OCT) provide detailed anatomical and functional information without the need for Injectable contrast media. These alternative imaging modalities offer advantages over contrast-enhanced imaging techniques, including reduced risk of adverse reactions and avoidance of ionizing radiation exposure. As a result, healthcare providers may increasingly opt for alternative imaging modalities over contrast-enhanced techniques, leading to a decline in demand for high-pressure contrast media injectors.
Covid-19 Impact
The COVID-19 pandemic had negatively impacted the high-pressure contrast media injector market. With healthcare systems worldwide overwhelmed by the influx of COVID-19 patients, non-urgent medical procedures, including diagnostic imaging, have been postponed or cancelled, leading to a decline in demand for contrast media injectors. Moreover, many hospitals and imaging centers faced operational challenges, such as staffing shortages, supply chain disruptions, and financial constraints.
The consumables segment is expected to be the largest during the forecast period
The consumables segment is estimated to hold the largest share. Consumables play a crucial role in supporting the operation and functionality of contrast media injection systems. Syringes are essential consumables that hold and deliver the contrast media to the injector system. Moreover, they come in various sizes and configurations to accommodate different injection volumes and flow rates. As a result, demand for consumables remains consistent and is closely related to the use of high-pressure contrast media injectors in clinical practice.
The single head injectors segment is expected to have the highest CAGR during the forecast period
The single head injectors segment is anticipated to have lucrative growth during the forecast period. These injectors are designed to deliver contrast media into the patient's bloodstream at a controlled rate and pressure through a single injection head or syringe. Furthermore, these injectors offer simplicity and ease of use, making them suitable for routine imaging procedures in healthcare settings. They are engineered to deliver precise volumes of contrast media with minimal variability, ensuring consistent image quality and diagnostic accuracy across imaging studies.
North America commanded the largest market share during the extrapolated period due to its advanced healthcare infrastructure, technological innovation, and high demand for diagnostic imaging procedures. The region encompasses the United States, Canada, and Mexico, where healthcare expenditure is substantial and there is a strong emphasis on medical advancements and patient care. Moreover, technological advancements and research and development initiatives in North America contribute to the continuous evolution of high-pressure contrast media injector technologies.
Europe is expected to witness profitable growth over the projection period. Europe's healthcare infrastructure is characterized by well-established hospitals, imaging centers, and academic institutions, providing access to state-of-the-art diagnostic imaging procedures. Furthermore, the region is home to several leading manufacturers of medical devices, including high-pressure contrast media injectors. These companies leverage the region's strong research and development capabilities, regulatory expertise, and quality standards to develop innovative injector technologies that meet the needs of healthcare providers and patients.
Key players in the market
Some of the key players in the High Pressure Contrast Media Injector Market include Guerbet Group, Bayers Healthcare LLC, Bracco Group, Ulrich GmbH & Co. KG, Medtron AG, GE Healthcare, NemotoKyorindo Co. Ltd, Apollo RT Co. Ltd, Vivid Imaging and Sino Medical Device Technology Co.
In September 2023, GE HealthCare and Mayo Clinic announced a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies.
In December 2022, Bayer announced the U.S. launch of the Bayer Science Collaboration Explorer (BSCE) as part of its ongoing efforts to enhance public trust in scientific innovations, processes, and R&D activities.
In November 2022, GE Healthcare announced agreement with ulrich medical aimed at enhancing its market position in the growing U.S. market. As per the agreement, these two companies will co-ordinate to develop and offer multi-dose contrast media injector in the country.
In March 2022, Bracco Imaging and Philochem, a subsidiary of the Philogen Group collaborated on the development of a molecule for diagnostic applications
In December 2021, Bracco Imaging announced a global strategic collaboration agreement with Guerbet for Gadopiclenol, a high-relaxivity, macrocyclic contrast agent. Bracco Imaging and Guerbet will manufacture, as well as support research and development for future indications of Gadopiclenol, which the parties will commercialize independently under different brands.